New trials to see if HIV virus can be ‘flushed out’: expert
- Pakistan High Commission staffer asked to leave India after leak of sensitive defence documents
- Cyrus Mistry hits back at Tata Group with slew of allegations: Fraudulent transactions, unethical ways
- Tata Sons vs Cyrus: Sebi, govt keep watch, BSE seeks clarification
- Kashmir is a matter for India, Pakistan to sort out: British PM Theresa May
- It's unfortunate, because it has set a terrible precedent: Farhan Akhtar on Johar-MNS deal
New clinical trials have been launched in the US and Europe to test whether HIV virus can be "flushed out" through a new approach of using anti-retrovirals and immune modulating agents, revealed Prof. Christine Katlama, Head of the AIDS Clinical Research Unit, Department of Infectious Diseases, Pitie-Salpetriere, Paris.
Katlama, who is in Pune to participate in the first annual meeting of the HIV Medicine Association, was impressed by the quality of research in India and hopes to invite Indian doctors to participate in a clinical research course in June in Europe this year.
The HIV Medicine Association's two-day meet begins on March 26 and will focus on educating physicians on aspects of HIV treatment, said Dr Sanjay Pujari, Director and Chief Consultant, Institute of Infectious Diseases.
Katlama told The Indian Express that despite controlling the virus in the US and Europe, many new infections are reported. "Can we eradicate the virus instead of just sustaining treatment...Can we lower levels enough to ensure a functional cure that can enable HIV positive people to safely stop antiretroviral therapy," said Katlama adding that the new trial launched in November last hoped to focus on a more potent strategy.
"Antiretrovirals would be combined with immune modulating agents to 'flush out' the latent cell reservoir by triggering silent integrated proviral DNA to start producing new virus. This will then be susceptible to the potent antiretroviral drug combination," says Katlama, adding that 30 people have been enrolled in the clinical trial being conducted by biopharmaceutical company Cytheris. Participants will intensify their current suppressive regimen by adding the 2 newest antiretroviral drug classes, along with interleukin 7 (IL-7) to activate resting CD4 T-cells, she explained.
Apart from Katlama , a host of experts will participate in the meeting, Pujari said.
- A letter like Cyrus Mistry’s could deepen the credibility crisis of Indian capitalism
- The transgender rights bill dilutes the private member’s bill passed by Rajya Sabha
- Diverse myths around the festival underpin Hinduism’s openness
- Polygamy and gender justice debate is more complicated than it is made out to be
- By brokering for MNS, Devendra Fadnavis has shown himself as a CM afraid of a bully
- Pak PM would do well to study the past before choosing Raheel Sharif’s successor